AbbVie (ABBV) Declares $1.18 Quarterly Dividend; 4.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
UPDATE: Abbvie (ABBV) PT Raised to $109 at UBS; Pipeline Emerging and Expanding
June 17, 2020 5:38 AM EDT(Updated - June 17, 2020 7:53 AM EDT)
(updated to add analyst comments)
UBS analyst Navin Jacob raised the price target on Abbvie (NYSE: ABBV) to $109.00 (from $96.00) while maintaining a Buy rating, noting the pipeline is emerging and expanding.
The analyst... More
AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUMA XC for Enhancement of Chin Region
June 15, 2020 8:15 AM EDTToday Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® VOLUMA XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21.1 As the category leader, the JUVÉDERM® Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest approval marks their fifth approved indication in the U.S.1-5
"When assessing facial anatomy, the chin is a critical component to facial balance, yet it is often overlooked. Due to its... More
